Department of Internal Medicine, University of California Davis, 4150 V St Suite 2400, Sacramento, CA 95817, USA.
Violence Prevention Research Program, University of California Davis, 2315 Stockton Blvd, Sacramento, CA 95817, USA.
Prev Med. 2021 Dec;153:106861. doi: 10.1016/j.ypmed.2021.106861. Epub 2021 Oct 20.
In 2015, California received funding to implement the Prescription Drug Overdose Prevention Initiative, a 4-year program to reduce deaths involving prescription opioids by 1) leveraging improvements to California's prescription drug monitoring program (PDMP) (i.e., mandatory PDMP registration for prescribers and pharmacists), and 2) supporting county opioid safety coalitions. We used statewide data from 2011 to 2018 to evaluate the Initiative's impact on opioid prescribing and overdose rates. Prescribing data were obtained from California's PDMP; fatal and non-fatal overdose data were obtained from the California Department of Public Health. Outcomes were monthly opioid prescribing rates and opioid overdose rates, modeled using generalized linear mixed models. Exposures were mandatory PDMP registration, presence of county coalitions, and Initiative support for county coalitions. Mandatory PDMP registration was associated with a 25% decrease (95%CI, 0.71-0.79) in opioid prescribing rates after 24 months. Having a county coalition was associated with a 2% decrease (95%CI, 0.96-0.99) in the opioid prescribing rate; receiving Initiative support was associated with an additional 2% decrease (95%CI, 0.97-0.98). Mandatory PDMP registration and county coalitions were associated with a 35% decrease (95%CI, 0.43-0.97) and a 21% decrease (95% CI, 0.70-0.90), respectively in prescription opioid overdose deaths. Both interventions were also associated with significantly fewer deaths involving any opioid but had no significant association with non-fatal overdose rates. Findings add to the knowledge available to guide policy to prevent high-risk prescribing and opioid overdoses. While further study is needed, coalitions and mandatory PDMP registration may be important components in such efforts.
2015 年,加利福尼亚州获得资金实施了“处方药物过量预防倡议”,这是一个为期 4 年的计划,旨在通过以下两种方式减少涉及处方类阿片类药物的死亡人数:1)利用加利福尼亚州处方药物监测计划(PDMP)的改进(即对开处方者和药剂师实施强制性 PDMP 注册);2)支持县阿片类药物安全联盟。我们使用 2011 年至 2018 年的全州数据,评估该倡议对阿片类药物开方和过量用药率的影响。开处方数据来自加利福尼亚州的 PDMP;致命和非致命药物过量数据来自加利福尼亚州公共卫生部。结果是每月阿片类药物开方率和阿片类药物过量用药率,采用广义线性混合模型进行建模。暴露因素是强制性 PDMP 注册、县联盟的存在以及倡议对县联盟的支持。强制性 PDMP 注册与 24 个月后阿片类药物开方率下降 25%(95%CI,0.71-0.79)相关。拥有县联盟与阿片类药物开方率下降 2%(95%CI,0.96-0.99)相关;获得倡议支持与另外 2%的下降(95%CI,0.97-0.98)相关。强制性 PDMP 注册和县联盟与处方类阿片药物过量死亡人数分别下降 35%(95%CI,0.43-0.97)和 21%(95%CI,0.70-0.90)相关。这两种干预措施也与任何阿片类药物相关的死亡人数显著减少相关,但与非致命性药物过量率没有显著关联。这些发现增加了可用于指导预防高危处方和阿片类药物过量的政策的知识。虽然还需要进一步研究,但联盟和强制性 PDMP 注册可能是这些努力的重要组成部分。